A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults. A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Formulations of the Vaccine Candidate BNT162b2 Against COVID-19 in Healthy Adults 18 Through 55 Years of Age.
Category & Conditions: Coronavirus Disease (COVID-19)
Medicine: PF-07302048 (BNT162)
ClinicalTrials.gov Identifier (NCT): NCT04816669
Protocol ID: C4591020
PrintDownloadOpen Plain Language Summary Result: Click here